Clin Pediatr Hematol Oncol.  2015 Oct;22(2):146-150. 10.15264/cpho.2015.22.2.146.

Two Cases of Infant Hemophilia A Patients with Inhibitors

• Yu DU
• Park JK
• Park YS

• KMID: 2084615
• DOI: http://doi.org/10.15264/cpho.2015.22.2.146

Abstract

Development of inhibitors is currently one of the most serious complications of hemophilia treatment. Typically, the propensity to develop an inhibitor is likely influenced by both genetic and non-genetic factors. Hemophilia patients with inhibitors are partially or completely refractory to traditional replacement of the deficient clotting factors and are at increased risk of bleeding as compared to patients without inhibitors. Several cases of infant hemophilia A with inhibitor have been reported in other countries, but no such patient has so far been reported in South Korea. We report two infants affected by hemophilia A with inhibitors, both of whom had bleeding episodes that were successfully treated with recombinant activated factor VII. Clinicians should remain aware of potential inhibitor development in infant hemophilia A patients and such patients should be carefully monitored.

Keyword

Hemophilia A; Factor VIII inhibitor; Infant

MeSH Terms

Factor VIIa
Hemophilia A*
Hemorrhage
Humans
Infant*
Korea
Factor VIIa